neurocoach.
My Care Plan
Explore optionsMedications

MEDICATIONS

Evenamide (investigational schizophrenia drug)

Investigational adjunct for treatment-resistant schizophrenia; FDA clinical hold at US study sites after a potential cardiac safety signal.

NeuroCoach · Evidence explorerSources checked 2026-10-11Editorial draft · clinical review pending

How it works

Evenamide is a sodium-channel modulator being investigated as an add-on to existing antipsychotics in treatment-resistant schizophrenia.

What the evidence says, use by use

Evidence is specific to the condition, population and—for devices—the exact product. One label never covers everything.

Schizophrenia & Psychosis: Adjunctive treatment of treatment-resistant schizophrenia

In clinical trials
Who was studied / who it’s for: Adults enrolled in clinical trials for treatment-resistant schizophreniaRegulatory status: Not FDA approved. As of October 11, 2026, the FDA clinical hold continues at US ENIGMA-TRS 2 study sites; enrollment continues outside the US.What this label means: Being formally studied. Access is usually through a research study with its own eligibility rules and risks.

An October 8 company disclosure reported four deaths among evenamide-treated participants across its studies versus one with placebo. Investigators assessed three as unrelated and one possibly related; the FDA identified a potential cardiac arrhythmia safety signal, but causation has not been established. No benefit from an experimental intervention should be presented without this context.

Sources: Newron Pharmaceuticals (October 8, 2026)

Who usually provides it

Only approved clinical research teams; not routine clinical care.

Cautions & things to know

  • Unresolved safety questions include possible arrhythmias, seizures and the clinical hold at US sites.
  • Raw trial death counts do not establish drug causation or an individual's mortality risk.
  • Clozapine and coordinated specialist services remain important established treatment pathways for treatment resistance, when suitable.

Questions for a clinician

Conversation prompts, not a treatment plan.

  • Is the diagnosis and treatment-resistant status fully reviewed, including trials of standard options?
  • What exactly is the current FDA hold and eligibility in our country?
  • What alternative approved treatments and safety monitoring are appropriate?

Educational, not medical advice. NeuroCoach is an educational and care-navigation resource, not a medical provider. Information about medications, supplements, therapies, devices, clinical trials and community experiences is provided for education and exploration and is not a recommendation, diagnosis or treatment plan. Evidence varies substantially among interventions. Decisions about medical or mental-health treatment should be made with an appropriately qualified healthcare professional. Do not start, stop or change medication, supplements or treatment based solely on information found here.

Sources

Sources checked 2026-10-11. Educational editorial draft; clinical review pending.

  1. FDA clinical hold, deaths and cardiac safety signal Newron Pharmaceuticals (October 8, 2026)